Antenatal Betamethasone for Women at Risk for Late Preterm Delivery (ALPS Trial)
Source: View publication →
In women with singleton pregnancies at risk for late preterm delivery, administration of antenatal betamethasone significantly reduced neonatal respiratory complications but increased the risk of neonatal hypoglycemia.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ALPS trial represents a paradigm shift in modern obstetrics by extending the evidence-based use of antenatal corticosteroids beyond the traditional 34-week gestational limit. By demonstrating a marked reduction in respiratory morbidity among late preterm infants, the trial prompted major obstetric guidelines (such as those from ACOG and SMFM) to recommend betamethasone for eligible pregnancies between 34 and 36 weeks. However, the accompanying rise in neonatal hypoglycemia underscores the necessity of targeted neonatal metabolic monitoring and carefully balancing risks and benefits in clinical practice.
Historical Context
Prior to the publication of the ALPS trial in 2016, antenatal corticosteroids were universally recognized as the standard of care to accelerate fetal lung maturity and prevent respiratory distress syndrome in early preterm deliveries (<34 weeks). However, their utility in the 'late preterm' window (34 weeks to 36 weeks and 5 days) remained uncertain, despite recognition that late preterm infants suffer higher rates of respiratory morbidity and NICU admissions than term infants. The ALPS trial effectively closed this critical evidence gap, fundamentally altering obstetric protocols for the management of impending late preterm birth.
Guided Discussion
High-yield insights from every perspective
How do antenatal corticosteroids like betamethasone accelerate fetal lung maturity, and why are infants born in the late preterm period (34 to 36 weeks) still at risk for respiratory morbidity despite being so close to term?
Key Response
This tests foundational knowledge of fetal lung development. Betamethasone stimulates Type II pneumocytes to upregulate the production of surfactant (specifically DPPC) and increases alveolar fluid clearance. While late preterm infants are close to term, their lungs are still in the later saccular or early alveolar stage, lacking sufficient mature surfactant and fluid-clearance mechanisms compared to full-term infants, predisposing them to Respiratory Distress Syndrome (RDS) and Transient Tachypnea of the Newborn (TTN).
A patient at 35 weeks and 2 days presents in active preterm labor. Based on the ALPS trial criteria and current ACOG guidelines, she is a candidate for betamethasone. What specific neonatal adverse effect must you anticipate, and how should this alter immediate postpartum management and pediatric team coordination?
Key Response
Residents must apply the trial's inclusion criteria to clinical practice while anticipating complications. The ALPS trial demonstrated a significant increase in neonatal hypoglycemia (24.0% in the betamethasone group vs. 15.0% in placebo). The pediatric team must be notified to implement early feeding protocols and rigorous blood glucose monitoring immediately after birth to prevent hypoglycemic brain injury.
The ALPS trial excluded multiple gestations and women who had previously received a course of antenatal corticosteroids. How do these exclusions limit the external validity of the trial for a twin gestation presenting at 35 weeks, and what is the pathophysiological rationale against administering 'rescue' steroid courses in the late preterm window?
Key Response
Fellows must understand the limits of trial data in subspecialty populations. Twins have a high baseline rate of late preterm birth but were excluded from ALPS; thus, efficacy and safety are extrapolated. Furthermore, repeated or 'rescue' steroid courses in the late preterm period are generally avoided due to diminishing respiratory benefits and cumulative risks of fetal growth restriction, hypothalamic-pituitary-adrenal (HPA) axis suppression, and potential adverse neurodevelopmental impacts.
While the ALPS trial demonstrated a reduction in transient respiratory morbidities (like TTN and mild RDS), the increase in neonatal hypoglycemia led to a higher rate of NICU admissions for glucose management in some centers. How do you counsel patients on this trade-off in real-world practice, and does preventing a transient respiratory issue justify interventions that may separate the mother and infant?
Key Response
This question addresses the nuanced art of attending-level shared decision-making. It highlights the clinical dilemma where an intervention successfully reduces one morbidity (respiratory support) but inadvertently increases another (hypoglycemia), potentially disrupting early maternal-infant bonding, skin-to-skin contact, and the establishment of breastfeeding due to NICU triage protocols.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ALPS trial utilized a composite primary outcome ranging from the need for CPAP or supplemental oxygen to severe interventions like mechanical ventilation or ECMO. What are the statistical and interpretative risks of using a composite endpoint where the components have vastly different clinical severities, and how does the treatment's effect on the least severe components drive the overall statistical significance?
Key Response
PhD-level critique requires evaluating endpoint selection. In ALPS, the composite outcome was primarily driven by reductions in milder respiratory interventions (like CPAP and transient oxygen). Severe outcomes like mechanical ventilation or death were too rare to show a difference. Combining these endpoints can artificially inflate the perceived clinical impact of the drug if readers assume it prevents all components of the composite equally.
Despite the randomized, double-blind, placebo-controlled design of the ALPS trial, maternal hyperglycemia is a known side effect of betamethasone. Could this physiological response have unblinded the obstetric or pediatric teams, leading to ascertainment bias regarding the secondary outcome of neonatal hypoglycemia? How would you expect the authors to control for this?
Key Response
A journal editor must look for subtle threats to validity, such as functional unblinding. If maternal blood sugars spiked (a known steroid effect), providers might guess the patient received betamethasone. This awareness could lead to more vigilant neonatal glucose screening in the treatment arm compared to the placebo arm, artificially inflating the detected rate of neonatal hypoglycemia through surveillance bias.
Following the ALPS trial, ACOG and SMFM recommended a single course of betamethasone for women at 34 0/7 to 36 6/7 weeks at risk of delivery within 7 days. Considering recent long-term follow-up data raising concerns about potential adverse neurocognitive outcomes in children exposed to late-preterm steroids, should the guideline committee downgrade this recommendation, and what specific counseling parameters should be mandated?
Key Response
Guideline committees must continuously weigh immediate benefits against long-term harms. While the original ALPS trial prompted rapid guideline adoption (ACOG Practice Bulletin 171), emerging pediatric follow-up studies suggest potential slight decreases in neurocognitive scores or increased behavioral issues following late preterm steroid exposure. This challenges the committee to decide if the evidence level still supports a strong recommendation or if it should transition to highly individualized, conditional shared decision-making.
Clinical Landscape
Noteworthy Related Trials
Liggins and Howie Trial
Tested
Antenatal betamethasone
Population
Women with planned or expected premature delivery before 34 weeks gestation
Comparator
Placebo
Endpoint
Incidence of respiratory distress syndrome (RDS) and neonatal mortality
ASTECS Trial
Tested
Antenatal betamethasone (two doses)
Population
Women undergoing elective cesarean section at term (37 weeks or later)
Comparator
Usual care
Endpoint
Admission to special care baby unit with respiratory distress
MACS Trial
Tested
Multiple courses of antenatal corticosteroids
Population
Women at 25-32 weeks gestation who remained at risk of preterm birth 14 or more days after an initial steroid course
Comparator
Placebo (single course only)
Endpoint
Composite of perinatal mortality, severe RDS, severe intraventricular hemorrhage, periventricular leukomalacia, or bronchopulmonary dysplasia
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis